vp-001
Gene therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 20, 2023 (NCT05902962)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- U4/U6 small nuclear ribonucleoprotein Prp31Supplementation
supplementation - PRPF31
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06852963 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2025 | PYC Therapeutics |
| NCT06455826 | Phase 1 | Jun 30, 2024 | PYC Therapeutics |
| NCT05902962 | Phase 1 | Apr 20, 2023 | PYC Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PYC Therapeutics | For profit | 3 | 3 | 2 | 2023 |
1 organizations
Page 1 / 1